diabetes header graphic


Information On Generic Glyburide
By Ammy
Generic glyburide used in the treatment of type-2 mellitus is a sulfonylurea agent to control the blood sugar level. This drug can also be used along with metformin drug. Generic glyburide also has side effects that can be treated. Mostly they are minor when serious side effects occur then medical attention is needed. Some of the side effects are nervousness, confusion, difficulty in concentration, hunger, breathing difficulties and severe skin reactions.

Generic glyburide interacts with certain type of food and drugs and increase the intensity of side effects. The physician should be informed if you are undertaking any other medications along with generic glyburide. Ask your physician the following questions before the intake of the drug

Whether generic glyburide suits you?
Can



generic glyburide be used?
How will generic glyburide work?
What are the side effects of generic glyburide?
What are the drugs that interact with generic glyburide?
What are the ways to reduce the side effects?

Some of the drugs that interact with generic glyburide are Warfarin, Rifampin, Beta-Blockers, Medicines used for fungal and yeast functions. The recommended dosage level is 1.25 milligrams once a day. If there is kidney problem or any other disease or you are above 65 years of age consult your doctor before taking.

Suppose if you have missed any dose, take it as soon as you remember. If it is almost time for next dosage then it is better to skip the dose. Overdose causes serious side effects and needs immediate medical attention. Changes in diet, exercise and some changes in lifestyle can increase the effectiveness of the medicine. Talk to your physician about lifestyle changes. Always consult your doctor before taking generic glyburide or any other medicine.

www.internationaldrugmart.com/glyburide.html




Here are some more diabetes articles...

A Few Things You Should Know About Omega-3 Fats
By Robert Spadinger
Omega 3 fats are polyunsaturated fatty acids that cannot be produced by the body and therefore must be obtained from external sources. Research has shown that omega 3 fatty acids may help to prevent Read more...
Green Tea May Prevent Type 2 Diabetes
By Farshid
Green tea extract may help prevent type-2 diabetes through improved glucose tolerance(NewsTarget) A new study by DSM Nutritional Products shows that epigallocatechin gallate, commonly known Read more...

Study of 24 Hour Blood Pressure and the Association to Complications to Type 1 Diabetes
<b>Conditions</b>:   Type 1 Diabetes;   Hypertension<br/><b>Intervention</b>:   <br/><b>Sponsor</b>:   Steno Diabetes Center<br/><b>Recruiting</b> - verified April 2010
A Study on the Prevalence of Obstructive Sleep Apnea in Patients With Type II Diabetes Mellitus
<b>Conditions</b>:   Obstructive Sleep Apnea;   Diabetes Mellitus<br/><b>Intervention</b>:   <br/><b>Sponsor</b>:   The University of Hong Kong<br/><b>Completed</b> - verified July 2010
Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus
<b>Condition</b>:   Diabetic Macular Edema<br/><b>Interventions</b>:   Drug: Ranibizumab;   Drug: ranibizumab;   Drug: ranibizumab<br/><b>Sponsor</b>:   Novartis Pharmaceuticals<br/><b>Not yet recruiting</b> - verified July 2010
To Evaluate if Wide Glucose Fluctuations Lead to Injury of Heart Nerves
<b>Condition</b>:   Type 1 Diabetes Mellitus<br/><b>Intervention</b>:   <br/><b>Sponsor</b>:   University of Michigan<br/><b>Recruiting</b> - verified May 2010
Optimized Strategy for Diabetic Patients With Critical Limb Ischemia(Part I)
<b>Conditions</b>:   Vascular Diseases;   Diabetes<br/><b>Interventions</b>:   Device: femoral-popliteal bypass;   Device: stent<br/><b>Sponsors</b>:   Peking Union Medical College Hospital;   Beijing Tongren Hospital;   Xuanwu Hospital, Beijing<br/><b>Not yet recruiting</b> - verified July 2010
Comparing Safety and Efficacy of NN5401 With Insulin Glargine in Subjects With Type 2 Diabetes: An Extension to Trial NN5401-3590
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Interventions</b>:   Drug: NN5401;   Drug: insulin glargine<br/><b>Sponsor</b>:   Novo Nordisk<br/><b>Recruiting</b> - verified July 2010
Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
<b>Condition</b>:   Type 2 Diabetes Mellitus<br/><b>Interventions</b>:   Drug: LIXISENATIDE (AVE0010);   Drug: Placebo<br/><b>Sponsor</b>:   Sanofi-Aventis<br/><b>Recruiting</b> - verified July 2010
Does Vitamin D Reduce Risk of Developing Type II DM in High Risk Individuals
<b>Condition</b>:   Type 2 Diabetes Mellitus<br/><b>Interventions</b>:   Drug: Vitamin D3;   Drug: Placebo<br/><b>Sponsor</b>:   King Faisal Specialist Hospital & Research Center<br/><b>Not yet recruiting</b> - verified July 2010
Does Vitamin D Improve Glycemic Control in Type II DM?
<b>Conditions</b>:   Diabetes Mellitus;   Vitamin D Deficiency<br/><b>Interventions</b>:   Drug: vitamin D3 2000 IU;   Drug: vitamin D3 5000 IU;   Drug: Placebo<br/><b>Sponsor</b>:   King Faisal Specialist Hospital & Research Center<br/><b>Not yet recruiting</b> - verified July 2010
Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes
<b>Conditions</b>:   Diabetes;   Insulin<br/><b>Intervention</b>:   Device: insulin dose software<br/><b>Sponsors</b>:   Park Nicollet Institute;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Hygieia, Inc;   International Diabetes Center at Park Nicollet<br/><b>Recruiting</b> - verified June 2010
Type 2 Diabetes and Obesity in Mexican Pimas: Gene-Environment Interaction
<b>Condition</b>:   Type 2 Diabetes Mellitus<br/><b>Intervention</b>:   <br/><b>Sponsor</b>:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)<br/><b>Recruiting</b> - verified June 2010
Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Intervention</b>:   Drug: Insulin Glargine<br/><b>Sponsor</b>:   Sanofi-Aventis<br/><b>Not yet recruiting</b> - verified July 2010
A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy
<b>Condition</b>:   Type 2 Diabetes<br/><b>Interventions</b>:   Drug: SK-0403;   Drug: Placebo;   Drug: Sitagliptin<br/><b>Sponsor</b>:   Kowa Research Institute, Inc.<br/><b>Not yet recruiting</b> - verified June 2010
Tu Salud Si Cuenta: UT Community Outreach Program for Community-based Diabetes Prevention and Control.
<b>Condition</b>:   Diabetes, Obesity<br/><b>Intervention</b>:   Behavioral: Tu Salud Si Cuenta Behavioral Intervention<br/><b>Sponsor</b>:   The University of Texas Health Science Center, Houston<br/><b>Recruiting</b> - verified July 2010
Hypothalamic Function Before and After Bariatric Surgery
<b>Conditions</b>:   Obesity;   Diabetes<br/><b>Interventions</b>:   Procedure: Roux en Y gastric bypass and lap. gastric banding;   Behavioral: Prodimed dietary intervention<br/><b>Sponsor</b>:   Leiden University Medical Center<br/><b>Recruiting</b> - verified January 2010
Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema
<b>Conditions</b>:   Diabetic Retinopathy;   Diabetic Macular Edema<br/><b>Intervention</b>:   <br/><b>Sponsor</b>:   National Eye Institute (NEI)<br/><b>Recruiting</b> - verified July 2010
Psoriasis Inflammation and Systemic Co Morbidities
<b>Condition</b>:   Psoriasis<br/><b>Intervention</b>:   <br/><b>Sponsors</b>:   Rockefeller University;   Weill Medical College of Cornell University<br/><b>Recruiting</b> - verified July 2010
The Effectiveness of Lubiprostone in Constipated Diabetics
<b>Conditions</b>:   Constipation;   Diabetes;   Colon Transit<br/><b>Intervention</b>:   Drug: Lubiprostone<br/><b>Sponsor</b>:   Emory University<br/><b>Not yet recruiting</b> - verified July 2010
Noninvasive Transcutaneous Glucometer Development
<b>Conditions</b>:   Healthy;   Prediabetic State (IGT);   Diabetes Mellitus, Type 2;   Diabetes Mellitus, Type 1<br/><b>Intervention</b>:   <br/><b>Sponsor</b>:   InLight Solutions<br/><b>Completed</b> - verified February 2008
Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation
<b>Conditions</b>:   Mitral Valve Insufficiency;   Atrial Fibrillation;   Heart Failure<br/><b>Intervention</b>:   Procedure: Cardiac catheterization<br/><b>Sponsors</b>:   Kaohsiung Veterans General Hospital.;   National Science Council, Taiwan<br/><b>Recruiting</b> - verified June 2010
Comprehensive Analyses of Multidetector-row Cardiac Computed Tomography Data in Koreans
<b>Condition</b>:   Coronary Disease<br/><b>Intervention</b>:   <br/><b>Sponsors</b>:   Seoul National University Bundang Hospital;   The Korean Society of Lipidology and Atherosclerosis<br/><b>Recruiting</b> - verified June 2010
Effect of Recombinant Human Growth Hormone (rhGH) Administration on Visceral Adiposity and Markers of Cardiovascular Risk in Obese Adolescent Girls
<b>Condition</b>:   Obesity<br/><b>Interventions</b>:   Drug: recombinant human growth hormone (rhGH);   Drug: Placebo<br/><b>Sponsors</b>:   Massachusetts General Hospital;   Genentech<br/><b>Recruiting</b> - verified July 2010
Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)
<b>Condition</b>:   Type 2 Diabetes Mellitus<br/><b>Intervention</b>:   Drug: Dapagliflozin<br/><b>Sponsor</b>:   Bristol-Myers Squibb<br/><b>Not yet recruiting</b> - verified July 2010
Prevention of Postprandial Hyperglycemia by Acarbose May be a Promising Therapeutic Strategy for Reducing the Increased Risk for Cardiovascular Disease.
<b>Condition</b>:   Diabetes Mellitus<br/><b>Intervention</b>:   Drug: Glucobay (Acarbose, BAYG5421)<br/><b>Sponsor</b>:   Bayer<br/><b>Completed</b> - verified July 2010
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
<b>Condition</b>:   Diabetes Mellitus, Type 2<br/><b>Interventions</b>:   Drug: insulin aspart;   Drug: insulin detemir;   Drug: insulin aspart;   Drug: insulin detemir<br/><b>Sponsor</b>:   Novo Nordisk<br/><b>Not yet recruiting</b> - verified July 2010
Effect of Pioglitazone on Mitochondrial Function in Muscle and Adipose Tissue in Humans
<b>Condition</b>:   Type II Diabetes Mellitus<br/><b>Intervention</b>:   <br/><b>Sponsors</b>:   Arizona State University;   Takeda Pharmaceuticals North America, Inc.<br/><b>Recruiting</b> - verified July 2010
Vitamin D in Vulnerable Adults
<b>Conditions</b>:   Frail Elderly;   Vitamin D Deficiency<br/><b>Interventions</b>:   Dietary Supplement: vitamin D;   Dietary Supplement: placebo<br/><b>Sponsor</b>:   Department of Veterans Affairs<br/><b>Not yet recruiting</b> - verified July 2010
Left Atrial Distensibility and Left Ventricular Filling Pressure in Acute Myocardial Infarction
<b>Condition</b>:   Myocardial Infarction<br/><b>Intervention</b>:   Procedure: Primary percutaneous coronary intervention<br/><b>Sponsors</b>:   Kaohsiung Veterans General Hospital.;   No other funding source in this study<br/><b>Completed</b> - verified December 2007
Use of Bevacizumab in Trabeculectomy Surgery
<b>Conditions</b>:   Glaucoma;   Optic Neuropathy;   Fibrosis<br/><b>Interventions</b>:   Drug: Bevacizumab;   Drug: Control<br/><b>Sponsors</b>:   Sunnybrook Health Sciences Centre;   Glaucoma Research Society of Canada<br/><b>Recruiting</b> - verified July 2010
Safety and Efficacy Study Comparing 3 New Types of Coronary Stents
<b>Conditions</b>:   Coronary Artery Disease;   Stents;   Coronary Thrombosis<br/><b>Interventions</b>:   Device: coronary stent placement;   Device: Coronary stent placement;   Device: coronary stent placement<br/><b>Sponsor</b>:   University Hospital, Basel, Switzerland<br/><b>Recruiting</b> - verified July 2010
Establishment of Biomarkers for Fabry Disease
<b>Condition</b>:   Fabry Disease<br/><b>Intervention</b>:   Other: Fluorescein angiography<br/><b>Sponsors</b>:   Ohio State University;   Genzyme<br/><b>Not yet recruiting</b> - verified July 2010
The Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) Study
<b>Conditions</b>:   Infant;   Obesity<br/><b>Interventions</b>:   Behavioral: Child Safety Insights;   Behavioral: Child Feeding Insights<br/><b>Sponsors</b>:   Penn State University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)<br/><b>Not yet recruiting</b> - verified July 2010
Anticholinergic vs. Botox Comparison Study
<b>Conditions</b>:   Urge Urinary Incontinence;   Overactive Bladder Syndrome<br/><b>Interventions</b>:   Drug: Botulinum toxin A (Botox A®);   Drug: Solifenacin 5mg;   Drug: Solifenacin 10mg;   Drug: Trospium chloride<br/><b>Sponsors</b>:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Office of Research on Women's Health (ORWH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)<br/><b>Recruiting</b> - verified June 2010
Reducing Dietary Energy Density by Incorporating Vegetables in Order to Decrease Energy Intake
<b>Condition</b>:   Obesity<br/><b>Intervention</b>:   Other: Incorporating vegetables into the diet to reduce energy density<br/><b>Sponsors</b>:   Penn State University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)<br/><b>Active, not recruiting</b> - verified July 2010